Physician profile
James Wallace
NPI 1265695126
$10,971.44
in general payments reported to CMS, 2019-2025
61 companies · $1,540 in 2025
The $1,540 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $661 · 2020: $1,007 · 2021: $2,285 · 2022: $2,035 · 2023: $1,817 · 2024: $1,626 · 2025: $1,540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,983.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,223.03 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $739.63 | 2019-2025 | |
| Pfizer INC. | $694.53 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $669.98 | 2019-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $569.84 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $523.91 | 2019-2025 | Repatha, Evenity, Otezla |
| Lilly USA, LLC | $493.25 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $447.66 | 2021-2025 | Freestyle Libre 3 |
| Ironwood Pharmaceuticals, INC | $435.44 | 2019-2025 | Linzess |
| Merck Sharp & Dohme LLC | $430.25 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $422.44 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $410.72 | 2022-2025 | |
| Forte Bio-Pharma LLC | $292.01 | 2020-2025 | Prolate, Nalocet, Tanlor |
| Janssen Pharmaceuticals, INC | $291.60 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $280.98 | 2019-2022 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.